Evidence & regulatory context
- Mechanism
- ChEMBL not queried in this run (time budget); resolved=false reflects absence of a lookup, not a negative result. ClinicalTrials.gov searched: 76 raw hits, ALL are haptoglobin genotype/phenotype or zonulin (pre-haptoglobin 2) biomarker studies (HIV, COPD, delirium, IBS, wound healing); NONE administers haptoglobin as an intervention. Zero relevant human trials recorded.
- Target
- Not recorded
- Injury models
- Burn
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatBurnScaldSprague-DawleyMalen = 30 rats in total across three groups, with 5 per group euth…IntraperitonealLow dose 4 mL (80 U)/kg with 16 mL/kg normal saline; high d…After the burn injury, exact interval not stated
Model: Full-thickness scald burn covering more than 30% of the dorsal skin surface under anaesthesia
Haptoglobin significantly reduced free haemoglobin at 24 hours and improved haematuria at the high dose, showed only a trend to lower interferon-gamma, produced no change in thrombin-antithrombin or plasmin-alpha2 plasmin inhibitor complexes, and increased clot firmness with shorter time to maximum…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.